Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $27.02, for a total transaction of $932,217.02. Following the completion of the sale, the chief executive officer directly owned 15,558 shares of the company’s stock, valued at approximately $420,377.16. This represents a 68.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Down 0.8%

Shares of MAZE traded down $0.22 during trading hours on Friday, reaching $26.43. 633,043 shares of the company traded hands, compared to its average volume of 665,641. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The company’s fifty day moving average price is $27.00 and its two-hundred day moving average price is $28.23. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). Equities research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reiterated an “outperform” rating and issued a $48.00 price target on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. HC Wainwright reissued a “buy” rating and set a $110.00 price objective on shares of Maze Therapeutics in a research note on Thursday, September 24th. Finally, Citigroup began coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $63.40.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares during the last quarter. TRV GP IV LLC purchased a new stake in Maze Therapeutics during the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the 2nd quarter valued at about $122,983,582. BlackRock Inc. bought a new stake in Maze Therapeutics during the 2nd quarter valued at about $104,525,000. Finally, Jupiter Topco LLC purchased a new position in Maze Therapeutics in the second quarter worth about $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.